Kodiak Sciences Inc. (KOD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by Kodiak Sciences Inc. on June 2, 2026. The filing details the results of three proposals submitted to security holders for a vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Proxies representing 55,026,544 shares, or 88.53% of total shares entitled to vote, were present and voted. The results for the three proposals were as follows:
- Proposal One (Election of Class II Directors): All three nominees were elected.
- Charles A. Bancroft: 38,940,529 For; 10,560,815 Withheld.
- Bassil I. Dahiyat, Ph.D.: 48,843,144 For; 658,200 Withheld.
- Taiyin Yang, Ph.D.: 49,192,610 For; 308,734 Withheld.
- Proposal Two (Advisory Approval of Executive Compensation): Approved by stockholders.
- For: 49,157,143
- Against: 323,196
- Abstain: 21,005
- Proposal Three (Ratification of Auditors): The appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, was ratified.
- For: 54,716,676
- Against: 52,962
- Abstain: 256,906
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the mechanics and results of the shareholder vote.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on April 22, 2026, for detailed background on the director nominees and executive compensation rationale.
- Note the significant number of broker non-votes (5,525,200) on the director election and executive compensation proposals.
- Confirm the tenure of the newly elected Class II directors, which extends until the 2029 annual meeting.
- Review the upcoming 2026 annual report to assess the financial health of the company, as this 8-K contains no financial data.